一种基于血液的炎症性肠病预后生物标志物
研究基于活动期炎症性肠病患者治疗前的血液样本,通过机器学习从全血基因表达中构建17基因qPCR分类器,将患者分为IBDhi与IBDlo两个亚组。在克罗恩病(n=66)和溃疡性结肠炎(n=57)独立验证队列中,IBDhi患者疾病更具侵袭性,需更早升级治疗,风险比分别为2.65和3.12。该分类器是首个经验证的、可预测新诊断IBD患者预后的生物标志物。
要点
- 17基因qPCR血液分类器可将IBD患者分为IBDhi与IBDlo两个亚组。
- IBDhi患者需更早治疗升级,克罗恩病风险比2.65,溃疡性结肠炎风险比3.12。
- 18个月内多次升级治疗的敏感性:克罗恩病72.7%,溃疡性结肠炎100%。
核心结论
- 这是首个经验证的、可预测新诊断IBD患者预后的生物标志物,是个体化治疗迈出的一步。
研究设计与样本
- 活动期IBD患者于治疗前入组,对纯化CD8 T细胞和/或全血进行转录组分析,并前瞻性收集表型数据。
- 通过CD8 T细胞转录组共识聚类识别IBD1/IBD2亚组,在训练队列中用机器学习从全血差异表达基因中筛选分类器,经qPCR优化后锁定最佳qPCR分类器。
- 在克罗恩病(n=66)和溃疡性结肠炎(n=57)独立队列中验证。
主要发现
- 在两个验证队列中,17基因qPCR分类器均将患者分为两个不同亚组。
- 无论基础诊断如何,IBDhi患者(类似于预后不良的IBD1亚组)疾病侵袭性显著高于IBDlo患者(类似于IBD2亚组),需更早升级治疗:风险比=2.65(克罗恩病),3.12(溃疡性结肠炎)。
- 随时间推移升级治疗次数更多:18个月内多次升级治疗的敏感性=72.7%(克罗恩病),100%(溃疡性结肠炎);阴性预测值=90.9%(克罗恩病),100%(溃疡性结肠炎)。
关键数值与推荐
- 17基因qPCR分类器将患者分为IBDhi与IBDlo两个亚组。
- 需更早升级治疗的风险比=2.65(克罗恩病),3.12(溃疡性结肠炎)。
- 18个月内多次升级治疗的敏感性=72.7%(克罗恩病),100%(溃疡性结肠炎);阴性预测值=90.9%(克罗恩病),100%(溃疡性结肠炎)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We have previously described a prognostic transcriptional signature in CD8 T cells that separates patients with IBD into two phenotypically distinct subgroups, termed IBD1 and IBD2. Here we sought to develop a blood-based test that could identify these subgroups without cell separation, and thus be suitable for clinical use in Crohn's disease (CD) and ulcerative colitis (UC). DESIGN: Patients with active IBD were recruited before treatment. Transcriptomic analyses were performed on purified CD8 T cells and/or whole blood. Phenotype data were collected prospectively. IBD1/IBD2 patient subgroups were identified by consensus clustering of CD8 T cell transcriptomes. In a training cohort, machine learning was used to identify groups of genes ('classifiers') whose differential expression in whole blood recreated the IBD1/IBD2 subgroups. Genes from the best classifiers were quantitative (q)PCR optimised, and further machine learning was used to identify the optimal qPCR classifier, which was locked down for further testing. Independent validation was sought in separate cohorts of patients with CD (n=66) and UC (n=57). RESULTS: In both validation cohorts, a 17-gene qPCR-based classifier stratified patients into two distinct subgroups. Irrespective of the underlying diagnosis, IBDhi patients (analogous to the poor prognosis IBD1 subgroup) experienced significantly more aggressive disease than IBDlo patients (analogous to IBD2), with earlier need for treatment escalation (hazard ratio=2.65 (CD), 3.12 (UC)) and more escalations over time (for multiple escalations within 18 months: sensitivity=72.7% (CD), 100% (UC); negative predictive value=90.9% (CD), 100% (UC)). CONCLUSION: This is the first validated prognostic biomarker that can predict prognosis in newly diagnosed patients with IBD and represents a step towards personalised therapy.
引用
- Biasci D, Lee JC, Noor NM, et al. A blood-based prognostic biomarker in IBD. Gut. 2019. PMID: 31030191. doi:10.1136/gutjnl-2019-318343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。